Gastroparesis is a gastrointestinal disorder characterized by delayed emptying of the stomach. It exists in acute and chronic forms and is a common disorder among patients with diabetes.
Patients presenting with acute episodes of gastroparesis require immediate hospitalization to manage pain, nausea, vomiting, glucose dysregulation, fluid and electrolyte imbalance, and potential malnutrition.
The most potent product for treating gastroparesis, Propulsid(R) (cisapride), achieved $1 billion in global sales, but was withdrawn from the market in 2000 due to adverse side effects.
Tranzyme plans to to initiate full Phase II development of TZP-101 in early 2007. In addition, the company is developing a second generation ghrelin agonist, TZP-102, which is expected to enter Phase clinical trials in the second half of 2007.
Source: Tranzyme
Comment Preview